Successful Treatment of Chronic Bone and Joint Infections with Oral Linezolid

Rao, Nalini; Ziran, Bruce H.; Hall, Robert M.; Santa, Elizabeth

doi:10.1097/01.blo.0000144860.11193.5e

Cited by 75 publications

(45 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most guidelines recommend vancomycin for MRSA infections and antistaphylococcal penicillins for MSSA, with or without adjunctive rifampin (543). Because vancomycin has poor bone penetration and low clinical cure rates, there is increasing interest in the use of alternative agents for MRSA osteoarticular infections, including linezolid (560,561), daptomycin (562), and rifampin in combination with either quinolones or fusidic acid (549,563). The only reported RCT addressing antibiotic choice for staphylococcal PJI in patients undergoing 2-stage replacement compared daptomycin with the "standard of care" (vancomycin, teicoplanin, or nafcillin) for 6 weeks in between the 2 stages in 75 adults with staphylococcal PJI (562).…”

Section: Prosthetic Joint Infectionmentioning

confidence: 99%

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

et al. 2015

View full text Add to dashboard Cite

SUMMARY Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to β-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.

show abstract

Section: Prosthetic Joint Infectionmentioning

confidence: 99%

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although linezolid, daptomycin, and tigecycline could be used to treat osteomyelitis due to MRSA in patients who display intolerance or poor response to vancomycin, experience with these newer MRSA-active agents for treating osteomyelitis is still limited [17][18][19][20]. In that regard, small prospective studies reported high rates of success when using linezolid to treat orthopedic infections [19,21]. For daptomycin, in vitro data suggested that this drug penetrates bone well [22], and data from the registry database indicated that it can be used successfully to treat osteomyelitis, especially in doses greater than 4 mg/kg [23].…”

Section: Antimicrobial Treatment Of Osteomyelitismentioning

confidence: 98%

Antimicrobial therapy for bone and joint infections

Aslam

Darouiche²

2008

Curr Infect Dis Rep

View full text Add to dashboard Cite

Bone and joint infections present a major therapeutic dilemma for health care providers from different medical and surgical specialties. There is a conspicuous lack of strong data on epidemiologic findings, financial impact related to loss of work, and rehabilitation cost in the area of bone infections. This review outlines the antimicrobial options and duration of therapy for osteomyelitis, prostheses-associated orthopedic infections, and septic arthritis.

show abstract

“…A literature search on MEDLINE over the period of 1966-2005 was performed using keywords ''vancomycin'', ''linezolid'', ''orthopaedic infection'' and ''methicillin resistant''. Data from eight reports were included [6,[10][11][12][13][14][15][16]. The pooled averages of treatment success and treatment completion for each treatment option were derived from the studies weighted against the number of patients in each study.…”

Section: Clinical Inputsmentioning

confidence: 99%